Carola Jüstel, Chief Executive Officer
Carola Jüstel carries over 20 years of international experience in the pharmaceutical industry in general management, commercial and R&D positions. Before joining Pepscan in September 2017 she was CEO of Octapharma Biopharmaceuticals GmbH in Germany where she and her team fully developed and manufactured a genetically engineered pharmaceutical blog-buster drug in the highly regulated GMP area for EMA and FDA approval for worldwide markets. After Octapharma she was Director of Production Support & Development at Sanquin Plasma Products B.V. for commercial production building up a center of expertise in order to optimally support external and internal customers. She studied in Berlin, Germany, and Caracas, Venezuela, received her B.Sc. degree in Biotechnology (Dipl.-Ing.) in 1995 at the University of Applied Sciences in Berlin and did several management development programs at INSEAD business school in Fontainebleau and Singapore.
Peter Timmerman, PhD, Chief Scientific Officer
Peter Timmerman joined Pepscan in 2001 and is responsible for scientific developments at Pepscan and in his role as CSO drives further advances in protein mimicry for peptide drug discovery program. He is inventor of the CLIPS technology and also holds a chair as Professor (by special appointment) in Protein Mimetic Chemistry at the University of Amsterdam. He studied Chemistry at the Vrije Universiteit (Amsterdam), and obtained his PhD summa cum laude from the University of Twente. In 1995, he was recipient of the Backer Prize for the best thesis in Organic Chemistry. He did post-doctoral research at the ETH in Zürich and was Assistant Professor in Supramolecular Chemistry and Technology at the University of Twente from 1995-2001. He is co-author of over 80 scientific papers and co-inventor on >10 patents.
Evert van Dijk, BSc, Chief Commercial Officer
Evert van Dijk is responsible for the manufacturing and supply chain of peptide products from Pepscan, in particular the Chemistry and Micro-array operations, as well as the worldwide peptide products and services business. As an early employee of Pepscan he has been instrumental in the development of most of Pepscan’s peptide products and services, e.g. peptide microarray technology. He was responsible for the development of the PepChip peptide array platform. His expertise is focused on protein-protein interactions and peptide chemistry, in particular solid phase peptide synthesis for antibody recognition. Mr. van Dijk has >15 years experience in executive leadership in biotech environment. He received his B.Sc. degree in Biochemistry in 1994 from the Hanze University of Applied Sciences in Groningen.
Hanne Kho, PharmD, Chief Operating Officer
Hanne Kho joined Pepscan in 2018 after working for 12 years at AstraZeneca and is responsible for manufacturing and supply chain of peptide products. He is an experienced pharmaceutical professional with 25+ years of experience in the pharmaceutical industry and have broad experience managing several pharmaceutical/business area’s. He also gained knowledge and experience on GMP, Operational Excellence and Lean. He studied Pharmacy at Leiden University in the Netherlands and received his Pharmacy degree in 1986 after which he worked at several Pharmaceutical companies.
Henk van der Meer, Chief Financial Officer
Henk van der Meer joined Pepscan in September 2008 as CFO. He has over 30 years of experience in finance. He studied Business Economics at Windesheim College in the Netherlands and was further educated in Information Management. Prior to joining Pepscan he held various positions of increasing responsibility at Rijkswaterstaat and Wageningen University. He was involved in incorporation, management and financing of university spin-out companies at Wageningen University. Throughout his career, he has acquired a wealth of experience in F&C, company valuations and corporate strategy.